The immune checkpoint inhibitor and anti-PD-L1 monoclonal antibody pembrolizumab improves relapse-free survival but not overall survival when compared with other adjuvant treatments for patients with high-risk resected melanoma.
A new study led by Cleveland Clinic researchers suggests that the small molecule ONC201 has promise as a less toxic treatment for pheohromocytomas/paragangliomas, and possibly other rare neuroendocrine tumors as well.
A new polygenic risk score offers improved breast cancer risk estimates for women of all ancestries in the United States.
A study shows that rates of hospitalization and mortality are high in oncology patients with COVID-19 but rates of invasive mechanical ventilation are low, suggesting that these patients may not be considered appropriate candidates for critical care interventions for the infection.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Homozygous inheritance of a common missense-encoding germline variation in HSD3B1 is associated with estrogen-driven postmenopausal breast cancer, according to a new study. This is the first-known mechanism that links germline inheritance to endogenous estrogen exposure and breast cancer.